Search

Background: Allergic asthma is a inflammatory disease defined as a condition of chronic airway inflammation. Asthma can be provoked by various stimuli like allergens inhalation like dust particles, pollen, and pollutants in the air. Objective: This exploration was dedicated to investigate the anti-asthmatic properties of tilianin against the ovalbumin (OVA)-initiated asthma in mice.MethodologyThe asthma was provoked to the mice via administering 100 μl of aluminum hydroxide containing 20 μg of OVA and treated with the 10 and 20 mg/kg of tilianin, respectively. The levels of Th2 cytokines, OVA-specific IgE, eotaxin, pro-inflammatory mediators, antioxidants, and other markers were inspected by marker specific assay kits. The mRNA expressions of TGF-β1, Smad, iNOS, and COX-2 was assessed using RT-PCR analysis. The lung histology was analyzed microscopically to detect the histological changes. Results: Tilianin treatment remarkably suppressed the IL-4, IL-5, and IL-13, IFN-γ, eotaxin, and IgE levels. The NO, MPO, and inflammatory makers TNF-α, IL-6, IL-12, and TXB2 was substantially diminished by the tilianin treatment. The TGF-β1, iNOS, and COX-2 expressions were appreciably suppressed by the tilianin. The histological findings proved that the tilianin treatment alleviated the OVA-provoked histopathological changes in the lung tissues. Conclusion: Our findings proved that tilianin effectively alleviated the OVA-provoked asthma in animals and it could be a talented anti-asthmatic candidate.

Lithium metal is the most promising high‐energy‐density anode. However, it is incompatible with high‐voltage cathodes in ether solvents due to their narrow electrochemical window. Herein, fluoroethylene carbonate (FEC) co‐solvent is introduced to regulate the Li+ solvation structures in ether solvents, including cyclic ether (1,3‐dioxolane [DOL]) and linear glymes with different chain lengths (1,2‐dimethoxyethane [DME], diglyme [G2] and triglyme [G3]). The apparently different effects of ether solvents on solvation ability and interaction strength with FEC are revealed. FEC plays a diverse role and function in 1 m lithium bis(trifluoromethanesulfonyl)imide (LiTFSI)‐ether/FEC electrolyte, thus relevant batteries perform distinct performances due to various ionic dynamics and solid‐electrolyte interphase. The Li+‐solvation structures are explored by Raman and nuclear magnetic resonance spectroscopies. Specifically, part of FEC molecules are inserted into the first solvation shell in 1 m LiTFSI‐DOL/FEC because of the weak solvation ability of DOL and strong interaction of DOL‐FEC, leading to few coordinated TFSI− and sluggish interfacial kinetics. In sharp contrast, FEC as a weak coordinated solvent almost exclusively occupies the second solvation sheath in 1 m LiTFSI‐glyme/FEC, favoring TFSI− coordination and rapid de‐solvation dynamics. Ultimately, the LiNi0.8Co0.1Mn0.1O2/Li battery in G2/FEC presents the most excellent performance, derived from abundant free‐FEC and rapid ionic kinetics. [ABSTRACT FROM AUTHOR]

Fast-charging batteries are highly sought after. However, the current battery industry has used carbon as the preferred anode, which can suffer from dendrite formation problems at high current density, causing failure after prolonged cycling and posing safety hazards. The phosphorus (P) anode is being considered as a promising successor to graphite due to its safe lithiation potential, low ion diffusion energy barrier, and high theoretical storage capacity. Since 2019, fast-charging P-based anodes have realized the goals of extreme fast charging (XFC), which enables a 10 min recharging time to deliver a capacity retention larger than 80%. Rechargeable battery technologies that use P-based anodes, along with high-capacity conversion-type cathodes or high-voltage insertion-type cathodes, have thus garnered substantial attention from both the academic and industry communities. In spite of this activity, there remains a rather sparse range of high-performance and fast-charging P-based cell configurations. Herein, we first systematically examine four challenges for fast-charging P-based anodes, including the volumetric variation during the cycling process, the electrode interfacial instability, the dissolution of polyphosphides, and the long-lasting P/electrolyte side reactions. Next, we summarize a range of strategies with the potential to circumvent these challenges and rationally control electrochemical reaction processes at the P anode. We also consider both binders and electrode structures. We also propose other remaining issues and corresponding strategies for the improvement and understanding of the fast-charging P anode. Finally, we review and discuss the existing full cell configurations based on P anodes and forecast the potential feasibility of recycling spent P-based full cells according to the trajectory of recent developments in batteries. We hope this review affords a fresh perspective on P science and engineering toward fast-charging energy storage devices. [ABSTRACT FROM AUTHOR]

Metformin has been involved in modulating inflammatory state and inhibiting cell proliferation and angiogenesis. This study aimed to determine whether metformin alleviates airway inflammation and remodeling of experimental allergic asthma and elucidate the underlying mechanism. We sensitized and challenged mice with ovalbumin (OVA) to induce allergic asthma. During the challenge period, metformin was administered by intraperitoneal injection. By histopathological and immunohistochemical analyses, metformin-treated mice showed a significant alleviation in airway inflammation, and in the parameters of airway remodeling including goblet cell hyperplasia, collagen deposition and airway smooth muscle hypertrophy compared to those in the OVA-challenged mice. We also observed elevated levels of multiple cytokines (IL-4, IL-5, IL-13, TNF-α, TGF- β 1 and MMP-9) in the bronchoalveolar lavage fluid, OVA-specific IgE in the serum and angiogenesis-related factors (VEGF, SDF-1 and CXCR4) in the plasma from asthmatic mice, while metformin reduced all these parameters. Additionally, the activity of 5′-adenosine monophosphate-activated protein kinase a (AMPK α) in the lungs from OVA-challenged mice was remarkably lower than control ones, while after metformin treatment, the ratio of p -AMPK α to AMPK α was upregulated and new blood vessels in the sub-epithelial area as evidenced by CD31 staining were effectively suppressed. These results indicate that metformin ameliorates airway inflammation and remodeling in an OVA-induced chronic asthmatic model and its protective role could be associated with the restoration of AMPK α activity and decreased asthma-related angiogenesis. [ABSTRACT FROM AUTHOR]